A diabetic-neuropathy experiment examined a non-benzodiazepine anxiolytic, so its findings cannot be assigned to the benzodiazepine class.
The researchers used streptozotocin-induced diabetic neuropathy in mice and tested etifoxine before or after symptoms developed. They reported reduced mechanical hypersensitivity and anxiety-like behavior. The article discusses direct and neurosteroid-related modulation of GABAA signaling as possible mechanisms.
Etifoxine is not a benzodiazepine, and shared involvement of GABAA signaling does not establish identical pharmacology. The study used animal behavior and laboratory disease induction, not human pain outcomes. Mechanistic discussion is not a clinical validation of a substitute treatment.
For testimony, name the actual compound and experimental system. This paper can illustrate that pharmacological categories matter even when pathways overlap. It does not show that diazepam, lorazepam, or another benzodiazepine provides the same analgesia, nor does it establish a safe or effective human neuropathy regimen.
Source reviewed: The non benzodiazepine anxiolytic etifoxine limits mechanical allodynia and anxiety like symptoms in (PMC8341594). Forensic applications above are interpretive analysis of the supplied paper.
Related reading: Zolpidem Withdrawal Seizures: Why Non-Benzodiazepine Chemistry Does Not Eliminate Related Risks; Remimazolam Anaphylaxis Despite Brotizolam Tolerance Does Not Establish Uniform Class Allergy.